These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 11188837)

  • 21. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
    Eigenmann C; Flepp M; Bernasconi E; Schiffer V; Telenti A; Bucher H; Wagels T; Egger M; Furrer H;
    Clin Infect Dis; 2003 Apr; 36(7):917-21. PubMed ID: 12652393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
    Le Moal G; Breux JP; Roblot F
    N Engl J Med; 2001 May; 344(21):1639-41. PubMed ID: 11374363
    [No Abstract]   [Full Text] [Related]  

  • 24. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis.
    Trikalinos TA; Ioannidis JP
    Clin Infect Dis; 2001 Dec; 33(11):1901-9. PubMed ID: 11692302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens.
    Atzori C; Clerici M; Trabattoni D; Fantoni G; Valerio A; Tronconi E; Cargnel A
    J Antimicrob Chemother; 2003 Aug; 52(2):276-81. PubMed ID: 12837736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
    N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary and secondary prevention of Pneumocystis carinii pneumonia with pentamidine aerosol. Effectiveness, side effects and incidence of extrapulmonary Pneumocystis carinii manifestations].
    Stoehr A; Plettenberg A; Albrecht H; Stellbrink HJ; Meigel W; Begemann F
    Med Klin (Munich); 1994 Mar; 89(3):132-5. PubMed ID: 8196573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuing Pneumocystis carinii prophylaxis.
    Girard PM
    N Engl J Med; 2001 Jan; 344(3):222-3. PubMed ID: 11172146
    [No Abstract]   [Full Text] [Related]  

  • 31. Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy.
    Powderly WG
    Clin Infect Dis; 2000 Aug; 31(2):597-601. PubMed ID: 10987727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
    Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
    Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Impact of zidovudine treatment and the pneumocystis carinii prophylaxis in natural history of patients with HIV infection].
    Sáiz Hervas E; Castilla Castellano V; Miquel Plaza J; Benito Blanco AM; Martín Llorens MM; Pastor de Blas M; Izquierdo P; Muñoz Jareño MA; Sierra A; Nieto MA; Moreno Collado AM; Fraguas C
    An Med Interna; 1998 Mar; 15(3):132-7. PubMed ID: 9580410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
    Kinloch-De Loës S; Hirschel BJ; Hoen B; Cooper DA; Tindall B; Carr A; Saurat JH; Clumeck N; Lazzarin A; Mathiesen L
    N Engl J Med; 1995 Aug; 333(7):408-13. PubMed ID: 7616989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
    Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
    Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.
    Sogaard OS; Lohse N; Gerstoft J; Kronborg G; Ostergaard L; Pedersen C; Pedersen G; Sørensen HT; Obel N
    Clin Infect Dis; 2008 Nov; 47(10):1345-53. PubMed ID: 18834317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
    Bender MA; Sax PE
    N Engl J Med; 2001 May; 344(21):1639; author reply 1640-1. PubMed ID: 11374364
    [No Abstract]   [Full Text] [Related]  

  • 39. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART.
    Chaiwarith R; Charoenyos N; Sirisanthana T; Supparatpinyo K
    AIDS; 2007 Jan; 21(3):365-7. PubMed ID: 17255744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Grünewald T; Behnsch M; Grobusch M; Vallée M; Wünsche T; Ruf B; Suttorp N
    J Infect; 2001 Jan; 42(1):8-15. PubMed ID: 11243747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.